Category: Latest News
-
Pharming Group shares slide after FDA issues Complete Response Letter for Joenja
Shares of Pharming Group NV (NASDAQ:PHAR) dropped around 16.8% in premarket trading on Monday after the company disclosed that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration for its supplemental New Drug Application covering Joenja. The FDA said it has concerns about possible underdosing in lower-weight pediatric patients for…
-
Yext shares slide as CEO pulls takeover bid
Shares of Yext (NYSE:YEXT) sank about 13% on Monday after Chief Executive Officer Michael Walrath withdrew his earlier, non-binding proposal to buy the remaining shares of the company he does not already own for $9.00 per share in cash. Walrath told Yext’s board that he was unable to line up financing at the proposed valuation.…
-
Avalo Therapeutics shares jump as Guggenheim starts coverage with Buy
Shares of Avalo Therapeutics Inc (NASDAQ:AVTX) climbed about 5.8% in premarket trading on Monday after Guggenheim launched coverage on the stock with a Buy recommendation and a $50 price target. Guggenheim analyst Yatin Suneja said he is encouraged by Avalo’s IL-1β inhibitor, AVTX-009, which is being developed to treat hidradenitis suppurativa (HS), a chronic inflammatory…
-
VerifyMe shares climb after company restores Nasdaq listing compliance
Shares of VerifyMe Inc (NASDAQ:VRME) advanced about 3.5% in premarket trading on Monday after the company said it has returned to compliance with Nasdaq’s minimum bid price rule. The provider of brand protection and specialized logistics services confirmed it received official notification from Nasdaq stating that it now meets the requirement to maintain a share…
-
Five market themes to track in the coming week
A packed calendar of U.S. economic data and high-profile corporate earnings could shape market direction in the days ahead. Investors will be watching the U.S. labour market closely, while results from major technology names such as Alphabet (NASDAQ:GOOG) and Amazon (NASDAQ:AMZN) are set to dominate headlines. Outside tech, Eli Lilly (NYSE:LLY) may offer fresh signals…
-
Coty teams up with OpenAI to roll out ChatGPT Enterprise companywide
Coty Inc. (NYSE:COTY) said it has entered into a strategic partnership with OpenAI to introduce ChatGPT Enterprise across selected parts of its global organization, marking a key step in the beauty group’s broader artificial intelligence strategy. Under the collaboration, Coty employees in targeted functions will gain access to OpenAI’s AI models through the ChatGPT Enterprise…
-
Twist Bioscience shares jump 5% after revenue tops forecasts and outlook is lifted
Twist Bioscience Corporation (NASDAQ:TWST) reported fiscal first-quarter 2026 revenue that came in ahead of market expectations on Monday, prompting a rally in the stock, even though earnings fell short of forecasts. Shares of the biotech group were up about 5.16% in premarket trading following the announcement. Twist posted quarterly revenue of $103.7 million for the…
-
Tyson Foods tops Q1 forecasts as prepared foods and chicken drive results
Tyson Foods, Inc. (NYSE:TSN) delivered a stronger-than-expected first quarter, with both adjusted earnings and revenue coming in ahead of forecasts, supported by solid momentum in its prepared foods business and continued market share gains in chicken. The food producer reported adjusted earnings per share of $0.97, beating the consensus estimate of $0.93. Revenue rose 5.1%…
-
Leerink cuts BioNTech to “market perform” after shares surge 24%
BioNTech SE (F:22UAy) (NASDAQ:BNTX) has been downgraded to “market perform” from “outperform” by Leerink Partners after a strong share price rally brought the stock closer to its near-term fundamental value. Leerink set a price target of $113 in a note published Monday, a move that sent BioNTech shares down more than 2%. The downgrade follows…
-
Aquestive shares jump despite FDA setback for Anaphylm
Aquestive Therapeutics (NASDAQ:AQST) shares surged 18% on Monday even after the company disclosed that it had received a complete response letter (CRL) from the U.S. Food and Drug Administration for Anaphylm, its sublingual film treatment for Type I allergic reactions, including anaphylaxis. The FDA’s feedback focused narrowly on packaging and administration-related concerns, particularly shortcomings identified…